Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation

Montalvá, Eva; Rodríguez‐Perálvarez, Manuel; Blasi, Annabel; Bonanad, Santiago; Gavín, Olga; Lladó, Laura; Llop, Elba; Laderas, Juan Carlos Pozo; Colmenero, Jordi

doi:10.1097/tp.0000000000004014

Cited by 26 publications

(26 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6] Improving the international normalized ratio distinguishes rising liver enzymes of preservation injury from graft-threatening complications, including primary nonfunction and hepatic artery thrombosis. [7] Other immediate complications include biliary leaks, which occur in 2%-25% of patients after transplant. [6] An early isolated bilirubin elevation, often in combination with abdominal pain, leukocytosis, and fevers should prompt cross-sectional imaging to look for fluid collections requiring endoscopic or percutaneous drainage.…”

Section: Immediate Period (Days 0-7)mentioning

confidence: 99%

Evaluation and management of abnormal liver enzymes in the liver transplant recipient: When, why, and what now?

Harding-Theobald

Kriss

2023

Clinical Liver Disease

View full text Add to dashboard Cite

Section: Immediate Period (Days 0-7)mentioning

confidence: 99%

Evaluation and management of abnormal liver enzymes in the liver transplant recipient: When, why, and what now?

Harding-Theobald

Kriss

2023

Clinical Liver Disease

View full text Add to dashboard Cite

“…Risk factors include pre-LT PVT, slow portal flow (after reperfusion) defined as <1300 mL/min or <65 mL/min/100 g, partial thrombectomy or vein intimal layer lesion during thrombectomy, nonphysiologically portal vein inflow reconstruction, and thrombophilic disorders in the recipient. In the absence of complications, therapy should be prolonged at least 2 months after LT and individualized thereafter [ 174 ].…”

Section: Treatmentmentioning

confidence: 99%

Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review

Odriozola

Puente

Cuadrado‐Lavín

et al. 2022

JCM

View full text Add to dashboard Cite

Portal vein thrombosis constitutes the most common thrombotic event in patients with cirrhosis, with increased rates in the setting of advanced liver disease. Despite being a well-known complication of cirrhosis, the contribution of portal vein thrombosis to hepatic decompensation and overall mortality is still a matter of debate. The incorporation of direct oral anticoagulants and new radiological techniques for portal vein recanalization have expanded our therapeutic arsenal. However, the lack of large prospective observational studies and randomized trials explain the heterogenous diagnostic and therapeutic recommendations of current guidelines. This article seeks to make a comprehensive review of the pathophysiology, clinical features, diagnosis, and treatment of portal vein thrombosis in patients with cirrhosis.

show abstract

“…Today, anticoagulation is strongly recommended to improve post-transplant outcomes for patients with PVT, who are candidates for LT surgery [ 27 ]. However, prophylaxis in these patients is challenging in the case of bleeding complications.…”

Section: Pathophysiology Of Deranged Hemostasis In End-stage Liver Di...mentioning

confidence: 99%

Individualized Management of Coagulopathy in Patients with End-Stage Liver Disease

et al. 2022

View full text Add to dashboard Cite

Over the last decades, individualized approaches and a better understanding of coagulopathy complexity in end-stage liver disease (ESLD) patients has evolved. The risk of both thrombosis and bleeding during minimally invasive interventions or surgery is associated with a worse outcome in this patient population. Despite deranged quantitative and qualitative coagulation laboratory parameters, prophylactic coagulation management is unnecessary for patients who do not bleed. Transfusion of red blood cells (RBCs) and blood products carries independent risks for morbidity and mortality, including modulation of the immune system with increased risk for nosocomial infections. Optimal coagulation management in these complex patients should be based on the analysis of standard coagulation tests (SCTs) and viscoelastic tests (VETs). VETs represent an individualized approach to patients and can provide information about coagulation dynamics in a concise period of time. This narrative review will deliver the pathophysiology of deranged hemostasis in ESLD, explore the difficulties of evaluating the coagulopathies in liver disease patients, and examine the use of VET assays and management of coagulopathy using coagulation factors. Methods: A selective literature search with PubMed as the central database was performed with the following.

show abstract

Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation

Abstract: on behalf of the Spanish Society of Liver Transplantation and the Spanish Society of Thrombosis and Haemostasis*

Cited by 26 publications

References 102 publications

Evaluation and management of abnormal liver enzymes in the liver transplant recipient: When, why, and what now?

Evaluation and management of abnormal liver enzymes in the liver transplant recipient: When, why, and what now?

Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review

Individualized Management of Coagulopathy in Patients with End-Stage Liver Disease

Contact Info

Product

Resources

About